^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

Published date:
09/28/2019
Excerpt:
Comparing protein expression, we found that cMYC (Fold change, FC:2.5; P = 0.015) and Vimentin (FC:1.66; P = 0.022) were top biomarkers of sensitivity, while high E-cadherin (FC:1.94; P = 0.046) and BCL-2 (FC:1.86; P = 0.032) associated with resistance.
DOI:
10.1093/annonc/mdz264